Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Chung

Showing results (161-170 of 177) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett, Yves Boucher, Dan G Duda, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
The New England Journal of Medicine|September 1, 2006
Celecoxib for the prevention of sporadic colorectal adenomasMonica M Bertagnolli, Craig J Eagle, Ann G Zauber, et al.
Trials|February 2, 2017
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trialDavid A Drew, Samantha M Chin, Katherine K Gilpin, et al.
Nature Medicine|September 11, 2019
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2019
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019Samir Gupta, Dawn Provenzale, Xavier Llor, et al.
Nature Medicine|July 3, 2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017Samir Gupta, Dawn Provenzale, Scott E Regenbogen, et al.
Lancet (London, England)|October 27, 2009
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M Maguire, Katherine A High, Alberto Auricchio, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018Dawn Provenzale, Samir Gupta, Dennis J Ahnen, et al.
Pageof 18

Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett, Yves Boucher, Dan G Duda, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
The New England Journal of Medicine|September 1, 2006
Celecoxib for the prevention of sporadic colorectal adenomasMonica M Bertagnolli, Craig J Eagle, Ann G Zauber, et al.
Trials|February 2, 2017
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trialDavid A Drew, Samantha M Chin, Katherine K Gilpin, et al.
Nature Medicine|September 11, 2019
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2019
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019Samir Gupta, Dawn Provenzale, Xavier Llor, et al.
Nature Medicine|July 3, 2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Yotam Drier, Koen M A Dreijerink, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017Samir Gupta, Dawn Provenzale, Scott E Regenbogen, et al.
Lancet (London, England)|October 27, 2009
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M Maguire, Katherine A High, Alberto Auricchio, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018Dawn Provenzale, Samir Gupta, Dennis J Ahnen, et al.
Pageof 18